<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365823">
  <stage>Registered</stage>
  <submitdate>18/02/2014</submitdate>
  <approvaldate>6/03/2014</approvaldate>
  <actrnumber>ACTRN12614000240640</actrnumber>
  <trial_identification>
    <studytitle>Influenza Specific Immunity After Vaccination in Recipients of Haematopoietic Stem Cell Transplantation Compared to Healthy Controls</studytitle>
    <scientifictitle>A Prospective Study to Evaluate the Immunogenicity and Efficacy of Inactivated Trivalent Influenza Vaccine in Children (&gt; or = 6 months to &lt; or =18 years of age) who have Undergone Allogeneic or Autologous Haematopoietic Stem Cell Transplant compared to Aged Matched Controls</scientifictitle>
    <utrn />
    <trialacronym>Influenza Vaccine HSCT study</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Haematopoietic Stem Cell Transplant patients
</healthcondition>
    <healthcondition>cancer
</healthcondition>
    <healthcondition>haematological malignancy
</healthcondition>
    <healthcondition>Autologous or allogeneic</healthcondition>
    <healthcondition>Influenza</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Trivalent Inactivated Influenza Vaccine 6 months to 2 years post transplant as per immunisation guidelines. Two doses of influenza vaccine at least 4 weeks apart are recommended for all HSCT recipients receiving influenza vaccine for the first time, with the 1st dose given as early as 6 months post transplant. This is given intramuscularly. </interventions>
    <comparator>comparing immunogenecity to healthy controls who will be given the vaccination as per the Australian immunisation guidelines. This means that children who are influenza vaccine naive and under 10 years of age will have two doses and the others will have one dose of the vaccine given intramuscularly.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To measure influenza specific Haemagglutinin Inhibition [HI] antibody levels by standarised method at WHO Collaborating Centre for Reference and Research on Influenza
</outcome>
      <timepoint>for one dose, prevaccinetion and between 4 to 8 weeks post dose. 
For two doses, prevaccination and between 4 to 8 weeks post each dose. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To identify the frequency and severity of microbiologically confirmed influenza illness in HSCT patients who received TIV during that influenza season. This is assessed by asking the patients to contact staff if they have an influenza like illness. If they fulfil the criteria, then they come in for medical assessment and nasal swab looking for respiratory viruses by IF +/_ PCR. If positive for influenza, the swab will be sent to WHO Collaborating Centre for Reference and Research on Influenza for specific strain typing to assess vaccine failure versus strain mismatch.

</outcome>
      <timepoint>Any time from enrolment to end of the influenza season (End of nov of enrolment year)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Age greater than or equal to 6 months to less than or equal to 18 years of age at time of vaccination and have undergone HSCT
2.HSCT recipients who are more than 6 months upto 2 years post transplant
</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Known contraindication to influenza vaccine as defined in the National Health and Medical Research Council (NHMRC) Immunisation Handbook (10th ed.)
2.Receipt of an inappropriate dose of influenza vaccine for age of child during the current year 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>23/05/2013</anticipatedstartdate>
    <actualstartdate>23/05/2013</actualstartdate>
    <anticipatedenddate>30/08/2015</anticipatedenddate>
    <actualenddate>12/05/2016</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>131</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>19/03/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,WA,VIC</recruitmentstate>
    <hospital>Princess Margaret Hospital - Subiaco</hospital>
    <hospital>The Royal Childrens Hospital - Parkville</hospital>
    <hospital>Royal Children's Hospital - Herston</hospital>
    <hospital>Womens and Childrens Hospital - North Adelaide</hospital>
    <postcode>6008 - Subiaco</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>4029 - Royal Brisbane Hospital</postcode>
    <postcode>5006 - North Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Princess Margaret Hospital for children</primarysponsorname>
    <primarysponsoraddress>Roberts Road
Subiaco  WA  6008 
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Australia
</fundingname>
      <fundingaddress>38-42 Wharf Road
West Ryde  NSW  2114
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Princess Margaret Hospital foundation</fundingname>
      <fundingaddress>Level 1, 68 Hay Street 
Subiaco  WA  6008 
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is looking at whether children who have had a bone marrow transplant produce protective antibodies after the flu vaccine. We will compare this to healthy children, and also look at how many children get the flu despite being vaccinated. 

Who is it for? 
You or your child may be eligible to join this study if you/they are aged between 6 months to 18 years, and have undergone haematopoietic stem cell transplant 6 months to 2 years ago. 

Study details 
Bone marrow transplant (BMT) patients have significant problems with their immune system. The rate of problems caused by the flu (influenza) is particularly high in these patients. Vaccination is the main way to prevent the flu and the problems it causes. Vaccination of children and adolescents may not only protect the children themselves, but may also significantly decrease the rate of transmission and consequently, the knock-on effects in the general population. There are many studies in adults that have looked at the immune response of the flu vaccine in patients post transplant. Response rates are poor and whilst the response improves over time with recovery of their immune system, it rarely reaches that of healthy controls. The rates reported are between 9-40%. The studies that have been done are small. There are limitations to these studies and importantly, there is minimal amount of data for children. To our knowledge, there have been no studies conducted looking at the immune response to the flu vaccine in children alone. In this study all participants will receive the influenza vaccine as per immunisation guidelines. After each vaccine dose (1-2 doses may be administered), participants will undergo a blood test to evaluate influenza specific antibody levels. Participants will also be monitored from enrolment to the end of the influenza season (end of November of enrolment year) in order to identify frequency and severity of influenza infection. 


</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>princess margaret Hospital HREC</ethicname>
      <ethicaddress>Roberts road 
Subiaco WA 6008</ethicaddress>
      <ethicapprovaldate>30/07/2013</ethicapprovaldate>
      <hrec>1988/EP</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>QLD Childrenâ€™s Health Services (RCH), HREC</ethicname>
      <ethicaddress>Level 3, Foundation Building
Royal Childrens Hospital
Herston Road
HERSTON QLD 4029

</ethicaddress>
      <ethicapprovaldate>4/12/2012</ethicapprovaldate>
      <hrec>HREC/12/QRCH/213</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Women and Childrens Hospital HREC</ethicname>
      <ethicaddress>Level 2, Samuel Way Building, 72 King William Road,  North Adelaide, South Australia 5006</ethicaddress>
      <ethicapprovaldate>23/03/2015</ethicapprovaldate>
      <hrec>HREC/15/WCHN/19</hrec>
      <ethicsubmitdate>10/02/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Rishi Kotecha</name>
      <address>Princess Margaret Hospital For children
Roberts Road,
SUBIACO
WA 6008</address>
      <phone>+61893408222</phone>
      <fax>+61 8 9340 8402</fax>
      <email>rishi.kotecha@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ushma Wadia</name>
      <address>Princess Margaret Hospital For children
Roberts Road,
SUBIACO
WA 6008</address>
      <phone>+61 8 93408222</phone>
      <fax>+61 8 9340 8402</fax>
      <email>ushma.wadia@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ushma Wadia</name>
      <address>Princess Margaret Hospital For children
Roberts Road,
SUBIACO
WA 6008</address>
      <phone>+61 8 93408222</phone>
      <fax />
      <email>ushma.wadia@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ushma Wadia</name>
      <address>As above</address>
      <phone>As above</phone>
      <fax />
      <email>As above</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>